{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:37:25Z","timestamp":1785296245947,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T00:00:00Z","timestamp":1359504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Publicly sponsored trials, conducted primarily by cooperative groups sponsored by the National Cancer Institute, and commercially sponsored trials are necessary to create new knowledge, improve the care of oncology patients, and develop new drugs and devices. Commercial sponsors launch clinical trials that will result in drug approval, label extension, expansion of market share, and an increase in shareholder value. Conversely, publicly sponsored trials seek to optimize therapy for a particular disease, create new knowledge, and improve public health; these trials can also result in label extension of a drug and even in initial drug approval. Publicly sponsored trials may combine and\/or compare drugs developed by different commercial sponsors, develop multimodality therapies (e.g., the combination of chemotherapy and radiation), or develop novel treatment schedules or routes of drug administration (e.g., intraperitoneal chemotherapy). Publicly sponsored trials are more likely to focus on therapies for rare diseases and to study survivorship and quality of life; these areas may not be a priority for commercial entities. Screening and prevention strategies have been developed almost exclusively by the public sector given the large sample size and long follow-up period needed to complete the trial and, therefore, the lack of short-term commercial gain. Finally, given the public nature of the funding, clinical investigators are expected to publish their results even if the outcomes are unfavorable for the investigational therapy. With the ongoing reorganization of the cooperative groups to form a national clinical trials network, opportunities exist to create a robust platform for biomarker discovery and validation through the expanded collection of well-annotated biospecimens obtained from clinical trial participants. Thus, publicly funded trials are vital to developing and refining new cancer treatments and disseminating results to the medical community and the general public.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-0423","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T03:53:05Z","timestamp":1359604385000},"page":"232-238","source":"Crossref","is-referenced-by-count":26,"title":["Publicly Funded Clinical Trials and the Future of Cancer Care"],"prefix":"10.1093","volume":"18","author":[{"given":"Richard L.","family":"Schilsky","sequence":"first","affiliation":[{"name":"Section of Hematology-Oncology, The University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,1,30]]},"reference":[{"key":"2021122308350718000_B1","volume-title":"A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program","author":"Institute of Medicine","year":"2010"},{"key":"2021122308350718000_B2","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cncr.25248","article-title":"Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program","volume":"116","author":"Minasian","year":"2010","journal-title":"Cancer"},{"key":"2021122308350718000_B3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122308350718000_B4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2021122308350718000_B5","article-title":"CALGB 40502\/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)","volume":"30","author":"Rugo","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B6","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122308350718000_B8","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.seminoncol.2008.07.008","article-title":"Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group","volume":"35","author":"O'Leary","year":"2008","journal-title":"Semin Oncol"},{"key":"2021122308350718000_B10","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122308350718000_B12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2005.10.202","article-title":"Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13","volume":"23","author":"Peters","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B13","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"2021122308350718000_B14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"2021122308350718000_B15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/jnci\/djp232","article-title":"Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO 17 trial","volume":"101","author":"Mittmann","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122308350718000_B16","volume-title":"Initial national priorities for comparative effectiveness research","author":"Institute of Medicine","year":"2009"},{"key":"2021122308350718000_B17","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1056\/NEJMoa032651","article-title":"A comparison of laparoscopically assisted and open colectomy for colon cancer","volume":"350","author":"Clinical Outcomes of Surgical Therapy Study Group.","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308350718000_B18","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2006.09.7758","article-title":"Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group","volume":"25","author":"Jayne","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archsurg.143.9.832","article-title":"Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States","volume":"143","author":"Bilimoria","year":"2008","journal-title":"Arch Surg"},{"key":"2021122308350718000_B20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa040587","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","volume":"351","author":"Hughes","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122308350718000_B21","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2011.39.4890","article-title":"Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population","volume":"30","author":"Soulos","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B22","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res"},{"key":"2021122308350718000_B23","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-09-1570","article-title":"KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803","volume":"15","author":"Ogino","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308350718000_B24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","article-title":"Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from Intergroup Trial CALGB 89803","volume":"18","author":"Ogino","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122308350718000_B25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2012.45.1096","article-title":"Biological determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene Recurrence Score in CALGB 9581","author":"Venook","year":"2013","journal-title":"J Clin Onol"},{"key":"2021122308350718000_B26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/JCO.2007.13.8081","article-title":"Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy\u2014Cancer and Leukemia Group B trial 30203","volume":"26","author":"Edelman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308350718000_B27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-11-2202","article-title":"Development and use of integral assays in clinical trials","volume":"18","author":"Schilsky","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122308350718000_B28","volume-title":"Compressing timelines for CTEP-supported cancer treatment trials: A response to the OEWG report","author":"National Cancer Institute.","year":"2013"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/2\/232\/41856782\/oncolo_18_2_232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/2\/232\/41856782\/oncolo_18_2_232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:48:43Z","timestamp":1640306923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/2\/232\/6398755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,30]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,1,30]]},"published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0423","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,2,1]]},"published":{"date-parts":[[2013,1,30]]}}}